YIJIA Group's Revenue Soars 900% on Consultancy Boom
Ticker: VNOV · Form: 10-K · Filed: Jul 24, 2025 · CIK: 1699709
| Field | Detail |
|---|---|
| Company | Yijia Group Corp. (VNOV) |
| Form Type | 10-K |
| Filed Date | Jul 24, 2025 |
| Risk Level | high |
| Sentiment | mixed |
Sentiment: mixed
Topics: Consultancy Services, Revenue Growth, Microcap, High Risk, Healthcare Segment, Acquisition, Single Revenue Stream
TL;DR
**VNOV's 900% revenue jump is a speculative bet on consultancy, but the lack of product sales makes it a high-wire act.**
AI Summary
YIJIA GROUP CORP. (VNOV) reported a significant increase in revenue for the fiscal year ended April 30, 2025, reaching $1,000,000, a substantial rise from $100,000 in the prior year. This 900% revenue growth was primarily driven by a surge in 'Consultancy Service Fee Income' which grew from $100,000 to $1,000,000, while 'Sales of Healthcare Products' remained at $0 for both periods. The company's net income is not explicitly stated but the substantial revenue increase suggests improved financial performance. A key business change was the acquisition of Nutripeak Trading Corporation, which became a wholly-owned subsidiary on October 31, 2024, expanding VNOV's healthcare segment. Risks include reliance on a single revenue stream (consultancy services) and potential integration challenges with Nutripeak. The strategic outlook appears focused on leveraging the Nutripeak acquisition to further develop its healthcare segment and diversify its service offerings beyond consultancy.
Why It Matters
YIJIA GROUP CORP.'s explosive 900% revenue growth, driven entirely by consultancy services, signals a potential turnaround for the microcap. For investors, this indicates a high-risk, high-reward play, as the company's fortunes are tied to a single, volatile revenue stream. Employees at Nutripeak Trading Corporation will see their roles integrated into a rapidly expanding, albeit narrowly focused, parent company. Customers of YIJIA's consultancy services are clearly finding value, but the lack of healthcare product sales suggests a competitive struggle in that segment. The broader market will watch if VNOV can sustain this growth and successfully diversify beyond its current consultancy focus.
Risk Assessment
Risk Level: high — The risk level is high due to the company's extreme reliance on a single revenue stream: 'Consultancy Service Fee Income' accounted for 100% of the $1,000,000 revenue in fiscal year 2025. 'Sales of Healthcare Products' generated $0 in revenue for both 2024 and 2025, indicating a lack of diversification and significant vulnerability to market shifts in the consultancy sector.
Analyst Insight
Investors should approach VNOV with extreme caution, recognizing the high-risk, high-reward profile. A deep dive into the sustainability and client base of their consultancy services is crucial before considering any investment, given the complete absence of product sales.
Financial Highlights
- revenue
- $1,000,000
- revenue Growth
- +900%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Consultancy Service Fee Income | $1,000,000 | +900% |
| Sales of Healthcare Products | $0 | 0% |
Key Numbers
- $1,000,000 — Total Revenue (Increased from $100,000 in the prior year, representing a 900% growth for fiscal year 2025.)
- $100,000 — Prior Year Revenue (Total revenue for the fiscal year ended April 30, 2024.)
- 900% — Revenue Growth (Percentage increase in total revenue from fiscal year 2024 to 2025.)
- $0 — Sales of Healthcare Products (Revenue generated from healthcare product sales for both fiscal years 2024 and 2025.)
- 2025-04-30 — Fiscal Year End (The end date of the reporting period for this 10-K filing.)
- 2024-10-31 — Acquisition Date (Date Nutripeak Trading Corporation became a wholly-owned subsidiary.)
Key Players & Entities
- YIJIA GROUP CORP. (company) — filer of the 10-K
- VNOV (company) — ticker symbol
- Nutripeak Trading Corporation (company) — wholly-owned subsidiary acquired by YIJIA GROUP CORP.
- SEC (regulator) — recipient of the 10-K filing
- Bloomberg (company) — publisher of financial news
FAQ
What was YIJIA GROUP CORP.'s total revenue for the fiscal year ended April 30, 2025?
YIJIA GROUP CORP.'s total revenue for the fiscal year ended April 30, 2025, was $1,000,000, a significant increase from $100,000 in the previous fiscal year.
How did YIJIA GROUP CORP.'s revenue streams change between fiscal years 2024 and 2025?
In fiscal year 2025, YIJIA GROUP CORP.'s revenue was entirely from 'Consultancy Service Fee Income' at $1,000,000, up from $100,000 in 2024. 'Sales of Healthcare Products' remained at $0 for both periods.
What was the key business change for YIJIA GROUP CORP. during the reporting period?
A key business change for YIJIA GROUP CORP. was the acquisition of Nutripeak Trading Corporation, which became a wholly-owned subsidiary on October 31, 2024, expanding its healthcare segment.
What are the primary risks associated with investing in YIJIA GROUP CORP. (VNOV)?
The primary risks for VNOV include its extreme reliance on 'Consultancy Service Fee Income' for 100% of its revenue, and the lack of diversification with $0 in 'Sales of Healthcare Products' for two consecutive years.
How does the acquisition of Nutripeak Trading Corporation impact YIJIA GROUP CORP.'s strategic outlook?
The acquisition of Nutripeak Trading Corporation on October 31, 2024, suggests YIJIA GROUP CORP. aims to develop its healthcare segment and potentially diversify its offerings beyond its current consultancy focus.
What is the significance of the 900% revenue increase for YIJIA GROUP CORP.?
The 900% revenue increase to $1,000,000 for YIJIA GROUP CORP. signifies substantial growth in its consultancy services, but also highlights a concentrated revenue base.
When was the 10-K filing for YIJIA GROUP CORP. submitted to the SEC?
The 10-K filing for YIJIA GROUP CORP. was filed with the SEC on July 24, 2025, covering the fiscal period ended April 30, 2025.
What industry does YIJIA GROUP CORP. primarily operate in, according to its SIC code?
According to its Standard Industrial Classification (SIC) code 5130, YIJIA GROUP CORP. is primarily categorized under 'WHOLESALE-APPAREL, PIECE GOODS & NOTIONS', although its current revenue is from consultancy.
What was the revenue from 'Consultancy Service Fee Income' for YIJIA GROUP CORP. in fiscal year 2025?
YIJIA GROUP CORP. generated $1,000,000 from 'Consultancy Service Fee Income' in fiscal year 2025, which represents 100% of its total revenue for that period.
What is the current state of YIJIA GROUP CORP.'s healthcare product sales?
YIJIA GROUP CORP.'s healthcare product sales generated $0 in revenue for both the fiscal years ended April 30, 2024, and April 30, 2025, indicating no current sales activity in this segment.
Risk Factors
- Over-reliance on Consultancy Services [high — operational]: The company's revenue is heavily concentrated in Consultancy Service Fee Income, which accounted for all reported revenue in fiscal year 2025. This single revenue stream presents a significant risk if demand for these services declines or if competition intensifies.
- Nutripeak Integration Challenges [medium — operational]: The acquisition of Nutripeak Trading Corporation on October 31, 2024, introduces potential integration risks. Failure to effectively integrate Nutripeak's operations, culture, or systems could hinder the expected synergies and negatively impact financial performance.
- Lack of Healthcare Product Sales [medium — market]: Despite the acquisition of a healthcare-focused company, YIJIA GROUP CORP. reported $0 in Sales of Healthcare Products for fiscal year 2025. This indicates a lack of traction or development in this segment, posing a risk to diversification efforts.
Industry Context
YIJIA GROUP CORP. operates within the broader wholesale and services sector, with a recent strategic pivot towards the healthcare segment through acquisition. The healthcare industry is characterized by innovation, regulatory scrutiny, and evolving consumer demands. The company's current revenue model, heavily reliant on consultancy, suggests a service-oriented approach rather than direct product sales in the healthcare space.
Regulatory Implications
As a publicly traded company, YIJIA GROUP CORP. is subject to SEC regulations and reporting requirements. The healthcare segment, even if currently limited to consultancy and product sales at $0, could eventually involve more stringent regulations related to product safety, marketing, and distribution if the company expands its offerings.
What Investors Should Do
- Monitor Nutripeak integration progress
- Assess diversification into healthcare products
- Evaluate sustainability of consultancy revenue
Key Dates
- 2025-04-30: Fiscal Year End — Marks the end of the reporting period for the 10-K filing, reflecting the company's financial performance and position.
- 2024-10-31: Acquisition of Nutripeak Trading Corporation — This strategic acquisition expanded the company's healthcare segment and is expected to be a key driver for future growth and diversification.
- 2024-05-01: Beginning of Fiscal Year 2025 — The start of the period during which the company achieved significant revenue growth, primarily from consultancy services.
- 2024-04-30: End of Fiscal Year 2024 — The prior year-end, providing a baseline for the substantial revenue growth observed in fiscal year 2025.
Glossary
- Consultancy Service Fee Income
- Revenue generated from providing advisory or professional services to clients. (This is the sole and primary source of revenue for YIJIA GROUP CORP. in fiscal year 2025, highlighting a critical aspect of the company's business model.)
- Sales of Healthcare Products
- Revenue derived from the sale of goods within the healthcare sector. (This revenue stream was reported as $0 for fiscal year 2025, indicating no sales activity in this segment despite the acquisition of a healthcare company.)
- Nutripeak Trading Corporation
- A company acquired by YIJIA GROUP CORP. on October 31, 2024, to expand its presence in the healthcare segment. (Its integration is a key strategic initiative and a potential source of both growth and operational risk for the company.)
Year-Over-Year Comparison
YIJIA GROUP CORP. has demonstrated exceptional revenue growth of 900% for fiscal year 2025, primarily driven by a substantial increase in Consultancy Service Fee Income from $100,000 to $1,000,000. In contrast, Sales of Healthcare Products remained at $0 for both periods. The company also completed the acquisition of Nutripeak Trading Corporation, a significant strategic move to bolster its healthcare segment, which introduces new integration risks not present in the prior filing.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on July 24, 2025 regarding YIJIA GROUP CORP. (VNOV).